How many samples are needed to infer truly clonal mutations from heterogenous tumours?
Abstract Background Modern cancer treatment strategies aim to target tumour specific genetic (or epigenetic) alterations. Treatment response improves if these alterations are clonal, i.e. present in all cancer cells within tumours. However, the identification of truly clonal alterations is impaired...
Main Authors: | Luka Opasic, Da Zhou, Benjamin Werner, David Dingli, Arne Traulsen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5597-1 |
Similar Items
-
Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
by: Mieke R. Van Bockstal, et al.
Published: (2020-04-01) -
Clonal evolution in liver cancer at single-cell and single-variant resolution
by: Xianbin Su, et al.
Published: (2021-02-01) -
Molecular evidence for the bi-clonal origin of neuroendocrine tumor derived metastases
by: Rinner Beate, et al.
Published: (2012-11-01) -
Comprehensive Profiling of Primary and Metastatic ccRCC Reveals a High Homology of the Metastases to a Subregion of the Primary Tumour
by: Paranita Ferronika, et al.
Published: (2019-06-01) -
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
by: Lasse Kjær
Published: (2020-07-01)